Search results
Results from the WOW.Com Content Network
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
On BioNTech's (BNTX) third-quarter earnings call, investors will likely focus on the sales performance of its COVID-19 vaccine Comirnaty, developed in partnership with Pfizer.
Next week’s earnings are of much significance for major market movements as Q2 is believed to be a quarter of significant recovery, with growth accelerating and the outlook for the coming ...
BNTX earnings call for the period ending September 30, 2024.
Image source: The Motley Fool. BioNTech Se (NASDAQ: BNTX) Q2 2024 Earnings Call Aug 05, 2024, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds. ... and a price target of $172. BioNTech’s oncology pipeline was ...
Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards ...
For premium support please call: 800-290-4726 more ways to reach us